Milestone Pharmaceuticals Inc. financials

MIST CIK 0001408443

Source: EDGAR filings · Built 2026-06-19T02:46:50Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -49.34M -28.88M -46.54M -52.74M
EBITDA -62.03M -42.00M -61.01M -59.55M -42.98M -50.61M
Working Capital 97.94M 65.80M 65.81M 65.66M 112.15M 142.53M
Net Debt -14.67M 29.48M 38.02M -5.14M -113.45M -71.37M
Return on Equity (ROE) -150.97% -315.81% -355.88% -88.00% -38.06% -34.91%
Return on Assets (ROA) -55.53% -54.99% -79.34% -78.39% -35.76% -33.32%
Current Ratio 8.01× 9.10× 10.11× 11.70× 17.55× 24.14×
Debt-to-Equity 1.40× 4.17× 3.09× 0.04× 0.01× 0.01×
Effective Tax Rate 0.03%
Cash Conversion Ratio 0.78× 0.69× 0.78× 0.90× 0.78× 1.02×
Accruals Ratio -0.12× -0.17× -0.18× -0.08× -0.08× 0.01×
CapEx Coverage -162.39× -874.18× -414.50× -192.90×
Free Cash Flow Per Share $-0.59 $-0.47 $-1.08 $-1.25

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Research and Development Expense 18.11M 14.36M 31.05M 39.83M 38.67M 34.49M
Operating Income (Loss) -62.14M -42.10M -61.10M -59.64M -43.07M -50.71M
Income Tax Expense (Benefit) -17.00K
Net Income (Loss) Attributable to Parent -63.06M -41.52M -59.69M -58.39M -42.85M -49.97M
Earnings Per Share, Basic $-0.75 $-0.67 $-1.39 $-1.38 $-1.02 $-1.70
Earnings Per Share, Diluted $-0.75 $-0.67 $-1.39 $-1.38 $-1.02 $-1.70

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 73.05M 25.31M 13.76M 7.64M 114.14M 72.31M
Assets, Current 111.92M 73.93M 73.03M 71.80M 118.92M 148.69M
Assets 113.56M 75.50M 75.23M 74.48M 119.85M 149.97M
Long-term Debt 57.19M 53.35M 49.77M
Liabilities, Current 13.98M 8.13M 7.23M 6.14M 6.78M 6.16M
Liabilities 71.79M 62.35M 58.45M 8.13M 7.25M 6.86M
Stockholders' Equity Attributable to Parent 41.77M 13.15M 16.77M 66.35M 112.60M 143.12M
Common Stock, Shares, Outstanding 106.24M 53.35M 33.48M 34.29M 29.90M 29.83M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -49.04M -28.85M -46.42M -52.47M -33.22M -50.73M
Payments to Acquire Property, Plant, and Equipment 302.00K 33.00K 112.00K 272.00K
Net Cash Provided by (Used in) Investing Activities 11.25M 8.28M 4.76M -57.12M 70.00M -70.00M
Net Cash Provided by (Used in) Financing Activities 85.53M 32.12M 47.79M 3.09M 5.05M 73.22M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (MIST CIK 0001408443), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

PMCB

PHARMACYTE BIOTECH, INC.

AKBA

AKEBIA THERAPEUTICS, INC.

GEN

Gen Digital Inc.